| Literature DB >> 34961231 |
Elizabeth Alejandra Motolinía-Alcántara1, Carlos Omar Castillo-Araiza2, Mario Rodríguez-Monroy3, Angélica Román-Guerrero1, Francisco Cruz-Sosa1.
Abstract
The large-scale production of plant-derived secondary metabolites (PDSM) in bioreactors to meet the increasing demand for bioactive compounds for the treatment and prevention of degenerative diseases is nowadays considered an engineering challenge due to the large number of operational factors that need to be considered during their design and scale-up. The plant cell suspension culture (CSC) has presented numerous benefits over other technologies, such as the conventional whole-plant extraction, not only for avoiding the overexploitation of plant species, but also for achieving better yields and having excellent scaling-up attributes. The selection of the bioreactor configuration depends on intrinsic cell culture properties and engineering considerations related to the effect of operating conditions on thermodynamics, kinetics, and transport phenomena, which together are essential for accomplishing the large-scale production of PDSM. To this end, this review, firstly, provides a comprehensive appraisement of PDSM, essentially those with demonstrated importance and utilization in pharmaceutical industries. Then, special attention is given to PDSM obtained out of CSC. Finally, engineering aspects related to the bioreactor configuration for CSC stating the effect of the operating conditions on kinetics and transport phenomena and, hence, on the cell viability and production of PDSM are presented accordingly. The engineering analysis of the reviewed bioreactor configurations for CSC will pave the way for future research focused on their scaling up, to produce high value-added PDSM.Entities:
Keywords: bioactive compounds; bioreactor engineering; cell suspension culture (CSC); medicinal plant; plant-derived secondary metabolites (PDSM)
Year: 2021 PMID: 34961231 PMCID: PMC8707313 DOI: 10.3390/plants10122762
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Classification and types of PDSM.
Characteristics and biological activities reported for PDSM in medicinal plants.
| Compound | Characteristics | Representative Compounds | Biological/Pharmacological Properties | References |
|---|---|---|---|---|
| Alkaloids | Complex organic molecules with a heterocyclic nitrogen ring. | Piperine; nicotine, vasicine; theobromine; caffeine; aconitine; atropine; quinine; capsaicin, ephedrine; paclitaxel; morphine; berberine; vincristine; | Chemotherapeutic agents; antiproliferative; antimicrobial and antiparasitic activities; analgesic, anti-hyperglycemic, Alzheimer’s and Parkinson’s diseases, stroke, epilepsy, fungicide. | [ |
| Phenolic compounds | They are diverse in structure, and present in common | Antioxidant, anti-inflammatory, | [ | |
| Terpenes | Synthesized from acetate via the mevalonic acid pathway. | Anti-hypertensive activity, antimicrobial, insecticide, fungicide, antioxidant, anticonvulsant, anti-tumor and neurotrophic effects, immune function, skin protection, UV protection, anticancer, antiparasitic, antihyperglycemic. | [ | |
| Sulfur-rich compounds (SRGs) | The structure is composed of a β-D-glucosyl residue linked by a sulfur atom. | Glutathione, glucosinolates, phytoalexines, thionines, | Enzyme regulator, intercellular signaling molecule, antitumor effect, Burkitt lymphoma treatment, anticancer. | [ |
PDSM from medicinal plants successfully produced in the in vitro plant cell culture, bioactivities, and yield comparison.
| Compound | Plant Species | Biological Activity/ | Extraction Yield | Type of Culture | Ref. | |
|---|---|---|---|---|---|---|
| Mother Plant | In Vitro Cell Culture | |||||
| Shikonin | Anticancer, antibacterial, anti-inflammatory, hepatic steatosis attenuator, antitumor, and antioxidants | 10−20 mg/g | 150−200 mg/g | CSC | [ | |
| 36.25 mg/L | HRC | [ | ||||
| Anthraquinones |
| Antimicrobial, antifungal, hypotensive, analgesic, antimalarial, gastroprotective, antioxidant, hepatoprotective and antileukemic, and mutagenic functions | 3 mg/g | 100–200 mg/g | HRC | [ |
| Rosmarinic acid |
| Antioxidant, anti-inflammatory, antiviral activities | 8.78–9.4 mg/g | 12.32–21.28 mg/g | CSC | [ |
|
| 23.53 mg/g | 31.25 mg/g | CSC | [ | ||
|
| 12 mg/g | 38 mg/g | CSC | [ | ||
|
| 30 mg/g | 270 mg/g | CSC | [ | ||
|
| 30 mg/g | 360 mg/g | CSC | |||
| Berberine |
| Effects antitumor, anticancer, lower blood lipid, lower blood glucose, anti-osteoporosis, anti-osteoarthritis, antibiotic, and anti-inflammatory | 0.1 mg/g | 0.8 mg/mL | CSC | [ |
|
| 20–40 mg/g | 132 mg/g | CSC | |||
|
| 1 mg/g | 178 mg/g | CCC | |||
| Ginsenosides |
| Antitumor, immunological, anti-inflammation, anticancer, antidiabetic, and cardiovascular-protective | 0.015–8 mg/g | 36.4–80 mg/g | HRC | [ |
| 3.4–28.9 mg/g | CSC | |||||
| 15.1–105.6 mg/g | ARC | |||||
|
| 20–50 mg/g | CSC | ||||
|
| 60 mg/g | CCC | ||||
| 71.94 mg/g | ARC | |||||
| 40 mg/g | CSC | |||||
| Diosgenin |
| Anticancer, antidiabetic, anticoagulant, antithrombosis, anti-inflammatory, antiviral, anti-ageing | 0.4−3 mg/g | 72 mg/g | CSC | [ |
| 3.5–16 mg/g | CCC | |||||
|
| 12 mg/g | CCC | ||||
| 1–5 mg/g | 8.64 mg/L | CSC | [ | |||
| 23 mg/g | CCC | [ | ||||
| Ajmalicine |
| Antihypertensive, obstructive circulatory diseases treatment | 3 mg/g | 63 mg/L | CCC | [ |
| 10 mg/g | CSC | [ | ||||
| 34 mg/L | HRC | |||||
| Paclitaxel |
| Anticancer | 0.02 mg/g | 1.5 mg/g | CSC | [ |
| Podophyllotoxin |
| Vigorous antimitotic and antiviral activities and anticancer | 0.5 mg/g | 1.57 mg/g | CCC | [ |
|
| 0.025 mg/g | 189.91 mg/g | CSC | |||
|
| 1.6 mg/g | 2 mg/g | CSC | |||
| Artemisinin | Treat multi-drug-resistant strains of falciparum malaria | 1–15 mg/g | 9.33–110.2 mg/L | CSC | [ | |
| Phenolic Acids |
| Antimicrobial, secretolytic, expectorant, and diuretic agent | 136.59 mg/g | 126.55 mg/g | CCC | [ |
| (rosmarinic, chlorogenic, and ferulic acid) | 189.91 mg/g | CSC | ||||
| Resveratrol | Reduced coronary heart disease mortality rates and atherosclerosis, inhibiting low-density lipoprotein oxidation, and carcinogenesis | NR | 277.89 µg/g | CSC | [ | |
CSC means cell suspension culture; HRC means hairy root culture; CCC means callus cell culture, ARC adventitious root culture; NR means not reported.
Figure 2General steps for obtaining cell suspension culture. PDSM means plant-derived secondary metabolites. * Schemes were created with BioRender.com.
Plant-derived products manufactured from plant CSC which have entered into the pharmaceutical industry. The list of products makes no claim to be complete.
| Product | Species | Pharmaceutical Use | Manufacturer, Tradename, and | Type of Culture | Reference |
|---|---|---|---|---|---|
| Rosmarinic acid |
| Anti-inflammatory | ANattermann & Cie. Gmbh, | CSC | [ |
| Echinacea polysaccharides |
| Immunostimulant, anti-inflammatory | Diversa, 75,000 L bioreactor | CSC | [ |
| Berberines |
| Anticancer; antibiotic; anti-inflammatory | Mitsui Chemicals, Inc., (75,000 Lbr) | CSC | [ |
|
| CSC | ||||
| Podophyllotoxin | Anticancer | Nippon Oil Company, Ltd. | CSC | [ | |
| OC | [ | ||||
| Docetaxel |
| Ovarian cancer treatment | Phyton Biotech, Inc., Taxotere (150 kg/year) | CSC | [ |
| Paclitaxel | Anticancer: FDA approved for the treatment of ovarian, breast, and lung cancers | Phyton Biotech, Inc., Taxol ® (1000 kg/year) | CSC | [ | |
| Samyang Genex Corporation., Genexol (32,000 Lbr) | CSC | [ | |||
| [ | |||||
| Scopolamine | Anticholinergic; antimuscarinic; motion sickness, nausea, and intestinal cramping | Sumitomo Chemical Co., Ltd., Tokyo, Japan | HRC | [ | |
| Shikonin |
| Anti-HIV, antitumor, anti-inflammatory | Xi’an NEO Biotech, Shikonin 95% | CSC | [ |
CSC: cell suspension culture; HRC: hairy root culture; OC: organ culture.
Comparison of bioreactor configurations commonly used for plant cell culture.
| Bioreactor Configuration | Schematic Diagram * | Description | Advantages | Disadvantages | Ref. |
|---|---|---|---|---|---|
| Bubble |
| It is classified in the pneumatic-type bioreactor. They are constructed in cylindric columns where gas injection represents the only energy entrance to the system. BC bioreactors operate under constant bubbling where gas flows from the bottom to the top through nozzles, perforated plates, or spray rings, allowing not only the aeration process, but also helping the mixing and circulation of the fluid, without the need to install mechanical accessories. | Simple structure as no mechanical force is required to shake. | High foam formation under high gas flow rates. | [ |
| Airlift (ALB) |
| It is classified in the pneumatic-type bioreactor. This configuration is considered reasonably like STR, excepting for the impeller. They are tower reactors where fluid broth is mixed with a gas stream, which is compressed and injected at the bottom of the discharge pipe. The gas–fluid mix allows the creation ofdifferences in density and upward displacement. It is more suitable for hairy root and somatic embryo cultures. | Easy maintenance and reduces the risk of contamination due to the absence of mobile parts. | High levels of foam formation under high gas flow rates. | [ |
| Stirred tank bioreactor (STB) |
| It is grouped in the mechanically agitated bioreactor. This bioreactor consists in a mixer (turbine or propeller) installed within the tank reactor and may be equipped with gassing inlet stream. It can operate in batch, semi-continuous, or continuous mode [ | Efficient fluid mixing systems. | High energy cost owing to mechanical agitation. | [ |
* Schemes were created with BioRender.com.
Comparison of operating conditions used for SCC in flask and bioreactor to produce PDSM. The list of examples makes no claim to be complete.
| Species | Compounds | Operation Variables Evaluated | Biomass | PDSM | Ref. | ||
|---|---|---|---|---|---|---|---|
| In Shake Flask | In | In Shake Flask | In Bioreactor | ||||
|
| Phenylethanoid glycosides | 50 mL SCC in 100 mL flask | 5.0 L SCC in STR 10 L | 14.16 g/L | 15.64 g/L | The acteoside content in CSC in the bioreactor was about threefold higher than that in the shake flask | [ |
|
| Verbascoside, | 50 mL SCC in 250 mL flasks | STR 2 L | 11.8 g/L | 13.62 g/L | The content of phenolics was twofold higher in STR. | [ |
|
| Anthraquinone | 25 mL SCC in 250 mL flasks | 1.0 L SCC in STR 2 L | 330 g/L | 220 g/L | Anthroquinone production was 2.5 times higher in STR | [ |
| Shikonin | 25 mL CSC in 250 mL flasks | Air-lift bioreactor | 1249.2 g/L | 480 g/L | The shikonin content was 2.6 times higher in the bioreactor than in the flask. Production remained without significant differences in both bioreactors | [ | |
| 100 rpm | 2 L working volume | ||||||
| 25 ± 2 °C | 25 ± 2 °C | ||||||
| Continuous light | Fg: 2 L/min (sparger ring) | ||||||
| (70 µmol/m2 s 1) | |||||||
| STR 2 L | 1249.2 g/L | 450 g/L | |||||
| Six-blade turbine impeller 100 rpm | |||||||
| Fg: 2 L/min | |||||||
| 25 ± 2 °C | |||||||
|
| Rosmarinic acid | 100 rpm | 7 L CSC in STR 10 L | Biomass was 8.4 times higher in bioreactor than in flask | Production increased 1.66 times in bioreactor | [ | |
| 25 ± 2 °C | Marine impeller 100 rpm | ||||||
| Fg: 25 L/min | |||||||
|
| Rosmarinic acid | 200 mL CSC in 1 L flask | 1 L CSC in culture bags 2 L | 13.6 g/L | 18.7 g/L | Production increased 2.5 times in bioreactor | [ |
| 110 rpm | Batch mode | ||||||
| 25 °C | 20–30 rpm | ||||||
| 25 °C | |||||||
| Fg: 0.1 vvm | |||||||
| Darkness | |||||||
| Resveratrol | 100 mL CSC in 300 mL flasks | STR 5 L | NR | ≈35 g DW | Production increased 1.15 times in bioreactor | [ | |
| 110 rpm | Marine impeller 110 rpm | ||||||
| 23 °C | Fg: 0.15 vvm | ||||||
| Darkness | |||||||
| Squalene | 100 mL CSC in 250 L flask | Airlift bioreactor 7 L | 1.05 mg/g | 1.25 mg/g | Production increased 1.71 times in bioreactor in four weeks of culture | [ | |
| 90 rpm | Batch mode | ||||||
| 28 °C | 70–80 rpm | ||||||
| Fg: 4 L/min | |||||||
| 28 ± 2 ° C | |||||||
NR means Not reported.
Models used to describe kinetics and deactivation in whole cells [137,140,141,142].
| Mathematical Equation | Conventional Name |
|---|---|
|
| Monod kinetics |
|
| Expanded Monod kinetics |
|
| Expanded Monod kinetics |
|
| Monod’s teacher Tessier kinetics. |
|
| Contois kinetics. |
|
| Logistic kinetics. |
|
| Cell deactivation kinetics |
Conditions used in bioreactors and their effect on the SCC.
| Species | Compounds | Bioreactor | Operating Conditions | Operation | Effect of the | Ref. |
|---|---|---|---|---|---|---|
|
| Phenolics (phenylethanoid glycoside and flavonoid contents) | STR of 2 L (ring diffuser) and 3 L (sintered diffuser), Rushton impeller | 26 ± 2 °C, photoperiod of 16 h light (50 µmol/m2 s)/8 h darkness | Stirring speeds (120 and 400 rpm) | In both bioreactors, a higher shear stress was observed at rates of 400 rpm, affecting the growth phases and parameters, resulting in the decrease in PDSM. | [ |
|
| Anthraquinones | STR of 8 L | 25 ± 0.1 °C, gamma-irradiated cell cultures, the agitation speed of the impeller was 60 rpm, working volume 5 L | Impeller type (helical ribbon, Rushton turbine) | Helical ribbon provided a homogeneous mix and lower shear stress compared to Rushton turbine. | [ |
|
| Antraquinones | Baffled flask | 25 ± 2 °C, the cultures were grown in presence or in absence of light with a 16 h photoperiod using cool white fluorescent tubes at a light intensity of approximately 90 mol/m2 s | Stirring speeds (100, 360 rpm) | The speed at 360 rpm had a negative effect on cell growth; however, it favored the production of PDSM | [ |
|
| Antraquinones | STR of 1.5 L, turbine impeller | 25 ± 2 °C, working volume of 1.0 L | Shear stress (450 rpm) | The speed of agitation affected cell viability; however, it favored the production of PDSM. | [ |
| Shikonin | Air-lif of 2 L | 25 ± 2 °C, the dissolved oxygen (2 L/min) | Bioreactor-type | No significant differences were obtained in the growth and production of PDSM in both bioreactors. | [ | |
| STR of 2 L, six-blade turbine impellers | 25 ± 2 °C, 100 rpm, dissolved oxygen (2 L/min) | |||||
|
| Phenylpropanoid glycosides (Verbascoside) | STR | 23 ± 1 °C, photoperiod, 33 rpm and continuous | Bioreactor-type | The production of PDSM was significantly higher in the STR bioreactor | [ |
| Phenolic acids (Ferulic and Rosmarinic acid) | Balloon bioreactor (BB) | |||||
|
| Berberine | STR of 2 L, Rushton turbine | 25 °C in the dark, working volume (1.75 L) | Stirrer speeds of 100–900 rpm | The 250-rpm speed favored cell growth and PDSM production | [ |
| 25 °C in the dark, working volume (1.75 L) and 250 rpm | Dissolved oxygen fluctuations (25, 35 and 50%) | Fluctuations in dissolved oxygen tension affected berberine accumulation in the | ||||
|
| Steroid glycosides | BC of 20 and 630 L | 26 ± 0.5 °C in darkness, working volume of 15 L and 550 L, semi-continuous regime. | Bioreactor volume | No significant effect of bioreactor volume was obtained on cell growth and PDSM production. | [ |
PDSM: plant-derived secondary metabolites; STR: stirred tank reactor; Fg: aeration flow rate; vvm: gas volumetric flow rate per unit volume of culture medium.